Quince Therapeutics, Inc. (QNCX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol QNCX
- Company Quince Therapeutics, Inc.
- Price $0.53
- Changes Percentage 305.92
- Change 0.40
- Day Low $0.25
- Day High $0.65
- Year High $4.55
- Year Low $0.13
- Market Cap $29,383,122
- Price Avg 50 EMA (D) $2.82
- Price Avg 200 EMA (D) $1.88
- Exchange NASDAQ
- Volume 1,490,075,173
- Average Volume 28,145,880
- Open $0.28
- Previous Close $0.13
- EPS -1.2
- PE -0.44
- Earnings Announcement 2026-03-03 12:00:00
- Shares Outstanding $55,681,490
Company brief: QUINCE THERAPEUTICS, INC. (QNCX )
- Healthcare
- Biotechnology
- Dr. Dirk Thye M.D.
- https://www.quincetx.com
- US
- N/A
- 05-09-2019
- US22053A1079
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.